FDA Grants Accelerated Approval to Zenbexus Plus Daratumumab and Hyaluronidase-fihj and Dexamethasone for Multiple Myeloma
The FDA granted accelerated approval to Bristol Myers Squibb’s Zenbexus (iberdomide) with daratumumab and hyaluronidase-fihj plus dexamethasone for adults with multiple myeloma after at least one prior therapy line. Full approval depends on confirmatory trials. In Phase III Excaliber-RRMM, MRD-negative complete response was 41% vs 21% at median 16 months.
How this was made
The 30-second read
Why it matters
The FDA decision is a primary, time-sensitive catalyst for BMY, supported by Phase III Excaliber-RRMM results showing higher MRD-negative complete response rates versus DVd, while explicitly requiring confirmatory trials for full approval.
Market read
Traders can treat this as a regulatory milestone with measurable efficacy readout (MRD-negative complete response) but with valuation uncertainty until confirmatory trial benefit is verified.
What to watch
Boxed warnings for embryo-fetal toxicity and thromboembolism could affect uptake, prescribing behavior, and risk-benefit discussions, especially in community settings.
Background
Zenbexus (iberdomide) is positioned as the first FDA-approved CELMoD, a cereblon-modulating protein degrader class, in combination with daratumumab, hyaluronidase, and dexamethasone for adult multiple myeloma patients after at least one prior line including a proteasome inhibitor and an immunomodulatory agent.
Ticker impact
FDA granted accelerated approval for Bristol Myers Squibb’s Zenbexus (iberdomide) plus daratumumab, hyaluronidase, and dexamethasone in relapsed/refractory multiple myeloma.
Likely positive bias for BMY around approval headlines, but upside may be tempered by accelerated-approval confirmatory-trial uncertainty.
The article is a direct FDA approval event for BMY’s product and includes efficacy details (MRD-negative complete response) plus boxed-warning and confirmatory-trial contingency, which typically limits full valuation certainty until confirmatory data.
Market effects
First FDA-approved CELMoD class can re-rate competitive expectations for cereblon-modulating protein degrader programs in multiple myeloma.
Primarily US regulatory catalyst; may spill over to global oncology/hematology peers with similar MRD-driven development strategies.
Could influence global treatment paradigms and investor sentiment toward targeted protein degradation platforms beyond the US.
Counterpoint
Accelerated approval based on MRD-negative complete response may not translate into durable survival benefit, so the market may fade the initial enthusiasm until confirmatory trials mature.
Key entities
- drugZenbexus (iberdomide)
First FDA-approved CELMoD regimen in multiple myeloma, approved in combination as ZDd.
- companyBristol Myers Squibb
Sponsor of Zenbexus; cited in the approval commentary and pipeline discussion.
- clinical_trialExcaliber-RRMM
Phase III trial evaluating ZDd versus daratumumab, bortezomib, and dexamethasone (DVd).
- drugmezigdomide
Another investigational CELMoD with an NDA under FDA review, with a PDUFA target date of May 13, 2027.
